Latest News about NVS
Recent news which mentions NVS
From Benzinga
Why Are Pharming Shares Trading Higher Today?
February 02, 2022
From Benzinga
The Daily Biotech Pulse: LogicBio Genome Editing Therapy Study Placed On Clinical Hold, Gilead Q4 Disappoints On Slowing Veklury Sales
February 02, 2022
From Benzinga
Novartis Expects FY22 Sales, Profit Growth; Sandoz Review Continues
February 02, 2022
From Benzinga
Earnings Scheduled For February 2, 2022
February 02, 2022
From Benzinga
Carlyle, Blackstone Mull $25B Buyout For Novartis' Sandoz Arm: Report
February 01, 2022
Tickers
NVS
From Benzinga
Is AbbVie Stock a Buy Now?
February 01, 2022
From Motley Fool
AT&T and 4 more unloved dividend stocks to buy in a ‘risk-off’ era
January 31, 2022
From MarketWatch
The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News
January 31, 2022
From Benzinga
1 Top Dividend Stock to Buy Right Now
January 28, 2022
From Motley Fool
Fractional Investment Opportunity In Beachfront Multifamily Property: Last Call To Invest
January 27, 2022
From Benzinga
2 Cheap Dividend Stocks With Yields Above 3%
January 27, 2022
From Motley Fool
2 Beaten-Down Cathie Wood Growth Stocks to Buy and Hold For 10 Years
January 25, 2022
From Motley Fool
A New Oral Therapy for Psoriasis Could Be Coming Soon
January 24, 2022
From Benzinga
What This FDA News Could Mean for AbbVie's Stock
January 24, 2022
From Motley Fool
Novartis Hopes to Have Another COVID Therapy on the Way
January 23, 2022
From Motley Fool
3 Under-the-Radar COVID Stocks
January 19, 2022
From Motley Fool
From InvestorPlace
3 Top Biotech Stocks to Buy Right Now
January 15, 2022
From Motley Fool
Where Will Biogen Be in 5 Years?
January 15, 2022
From Motley Fool
The Daily Biotech Pulse: Bausch Files For Eye Health Unit IPO, LumiraDx Antigen Test Can Detect Omicron, Molecular Partners Discloses Fund Stake
January 14, 2022
From Benzinga
7 Best Long-Term Stocks to Buy and Hold for the Next Decade
January 13, 2022
From InvestorPlace
Why Molecular Partners Stock Crushed the Market Today
January 10, 2022
From Motley Fool
Here’s the market move Cathie Wood says is ‘ridiculous’ as her flagship fund sputters
January 10, 2022
From MarketWatch
Novartis To In-License COVID-19 Treatment From Molecular Partners, After Encouraging Mid-Stage Data
January 10, 2022
From Benzinga
From MarketWatch
Pfizer Snagged Another Approval for This Immunology Drug
January 03, 2022
From Motley Fool
Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates
December 31, 2021
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.